Nikhil Gadre

𝐑𝐄𝐆𝐔𝐋𝐀𝐓𝐎𝐑𝐘 𝐑𝐎𝐔𝐍𝐃𝐔𝐏 ⚛️ The FDA has released new draft guidance recommending best practices for multi-regional clinical trials (MRCTs) in oncology. Sponsors are encouraged to ensure that the outcomes of global oncology clinical development programs are understandable for US patients in support of marketing applications. 🌐 The FDA's final guidance on decentralized clinical trials (DCTs) clarifies several concerns raised by clinical experts and industry stakeholders regarding the earlier draft. This includes detailed requirements for maintaining a task log for healthcare providers, guidelines for physical inspections, and addressing challenges related to data variability in DCTs. 🤖 As the use of artificial intelligence (AI) tools, particularly generative AI, expands, experts remind regulatory professionals to prioritize the human aspect. Although these tools offer significant benefits, they necessitate human oversight and interpretation to be fully effective. During the opening plenary session, experts discussed how AI can be utilized across various sectors, the potential of this technology, and the hurdles in achieving its full benefits. Panelists included Ryan Kurtzman from the City of Long Beach, Bradley Thompson of Epstein Becker Green, Michelle Jump from MedSec, and Jay Mashburn from Recursion Pharmaceuticals, with moderation by Megha Iyer of Thermo Fisher Scientific. 🧬 As biosimilars gain market presence, they are generating competition with original products. However, patient adoption of biosimilars varies based on demographics, location, care setting, prescriber specialties, and types of insurance, according to two recent studies in Health Affairs. 🌐 The FDA has observed a rise in complete response letters (CRLs) issued to sponsors of biologics license applications (BLAs) over the last decade, with facility deficiencies being the most common reason cited, according to Leslie Rivera Rosado, a supervisory interdisciplinary scientist at the agency's Center for Drug Evaluation and Research (CDER). #Pharmaceuticals #Biotechnology #LifeSciences #PharmaNews #Biotech #HealthcareInnovation #DrugDevelopment #ClinicalResearch #Biopharma #PharmaTech #MedicalResearch #Healthcare #BioPharmaceuticals #PharmaIndustry #BiotechIndustry #PharmaCareers #MedicalInnovation #NewDrugs #Genomics #BiotechNews

14

💥 SUPER MSL: The Quest to Become the TOP MSL on Your Team💥 Don't miss this weeks MSL Talk podcast with Daniel Snyder, Ph.D., Senior Medical Affairs & HEOR Leader who discusses the differentiators for MSLs that will make you stand out and become the top MSL on your team. Learn more about….   👉 The qualities and differentiators of a “Super MSL” 👉 The skills and attributes that make MSLs stand out relative to their peers 👉 What common mistakes do MSLs need to avoid to 👉 What MSL Team leader should do to encourage and entice ideal MSL skills The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLtalk #careers  

32

3 Comments

💥 SUPER MSL: The Quest to Become the TOP MSL on Your Team💥 Don't miss this weeks MSL Talk podcast with Daniel Snyder, Ph.D., Senior Medical Affairs & HEOR Leader who discusses the differentiators for MSLs that will make you stand out and become the top MSL on your team. Learn more about…. 👉 The qualities and differentiators of a “Super MSL” 👉 The skills and attributes that make MSLs stand out relative to their peers 👉 What common mistakes do MSLs need to avoid to 👉 What MSL Team leader should do to encourage and entice ideal MSL skills The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLtalk #careers

27

1 Comment

Led by Markus Renschler, MD, Light Horse Therapeutics has made significant progress in the oncology space with a $62M #SeriesA funding round led by MPM BioImpact and Omega Funds, alongside Novartis Venture Fund. This marks a big step for their work in developing LHT-001, a promising candidate targeting critical cancer pathways. In parallel, their partnership with Novartis could be worth up to $1B, combining Light Horse's innovative pipeline with Novartis' expertise in oncology drug development and commercialization. This collaboration has the potential to address unmet needs in cancer treatment and accelerate progress in this critical field. #Biotech #Oncology #Immunology #Innovation #LightHorseTherapeutics #Novartis #MPMBioImpact #OmegaFunds

7

💥 Why Chasing Titles is Fools Gold 💥   Don't miss this weeks MSL Talk Podcast with Archie Stone, PhD, Vice President Product Development at Aurinia Pharmaceuticals Inc. who discusses career development strategies and why chasing titles can lead to "fools gold".   Learn more about….   👉 The importance of titles in medical affairs 👉 How companies determine titles and levels 👉 The universal standard for titles and levels (or lack thereof) 👉 Why rock climbing is a good analogy for career progression 👉 Common mistakes people are making in their careers 👉 Advice for job seekers to find career success   The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers  

31

2 Comments

💥 Why Chasing Titles is Fools Gold 💥 Don't miss this weeks MSL Talk Podcast with Archie Stone, PhD, Vice President Product Development at Aurinia Pharmaceuticals Inc. who discusses career development strategies and why chasing titles can lead to "fools gold". Learn more about…. 👉 The importance of titles in medical affairs 👉 How companies determine titles and levels 👉 The universal standard for titles and levels (or lack thereof) 👉 Why rock climbing is a good analogy for career progression 👉 Common mistakes people are making in their careers 👉 Advice for job seekers to find career success The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

7

1 Comment

💥 Why Chasing Titles is Fools Gold 💥 Don't miss this weeks MSL Talk Podcast with Archie Stone, PhD, Vice President Product Development at Aurinia Pharmaceuticals Inc. who discusses career development strategies and why chasing titles can lead to "fools gold". Learn more about…. 👉 The importance of titles in medical affairs 👉 How companies determine titles and levels 👉 The universal standard for titles and levels (or lack thereof) 👉 Why rock climbing is a good analogy for career progression 👉 Common mistakes people are making in their careers 👉 Advice for job seekers to find career success The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

52

7 Comments

Attention Life Science Professionals! 🔥 ANOTHER HOT TOPIC ALERT! 🧪🔬 Some More Good News in the Life Sciences! Check out the summary below regarding the 3,000 jobs created in Boston area in 2024. Share your thoughts in the comments! And if you are looking for folks, please let us know! hashtag #lifesciences #biotech #pharma #medicaldevice #diagnostics #hiring2024 #boston The Richmond Group USA

6

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL   Learn more about….   👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others   The MSL Talk Podcast will be available Tuesday May 14th, 2024 on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers  

15

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL Learn more about…. 👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

15

2 Comments

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL Learn more about…. 👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

14

5 Comments

𝗧𝗵𝗲 𝗡𝗞 𝗰𝗲𝗹𝗹 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗶𝘀 𝗵𝗲𝗿𝗲 🦠 Artiva Biotherapeutics raises $167M in an upsized RPO to advance its pipeline of autoimmune and cancer therapeutics. The majority of the IPO proceeds will finance clinical development of a non-genetically modified, cryopreserved NK cell therapy called AlloNK. The candidate is currently in a phase 1 #lupus nephritis trial in combination with Roche's Rituxan or Gazyva, and AlloNK also features in a separate basket study in multiple autoimmune indications. https://lnkd.in/gacfyV4C

31

1 Comment

🚀 Genmab Expands Partnership with Scancell in $630M Deal! Genmab has deepened its collaboration with Scancell, licensing a second anti-glycan antibody from the GlyMab platform. This strategic move, following a 2022 agreement, raises the partnership's potential value to $1.27 billion. 💡 What’s New? GlyMab Technology: Targets glycans, sugars critical to cancer progression, offering high tumor specificity. Exclusive Rights: Genmab will develop and commercialize across multiple therapeutic modalities. Scancell CSO Lindy Durrant says the deal validates GlyMab's ability to generate innovative cancer therapies. #CancerResearch #BiotechInnovation #Genmab #Scancell #OncologyBreakthroughs #Partnerships

2

1 Comment

Some noticeable licensing and fundraising deals yesterday in the Biotech Space: Vertex Pharmaceuticals agree to license Orum Therapeutics degrader-antibody conjugate technology for $15 million upfront plus $310 million per target in milestones plus royalties on future sales - Greg Dwyer Cardurion Pharmaceuticals announce a $260M Series B who have now raised over $500M – funds will be used to advance it’s pipeline for Cardiovascular diseases. Neuspera Medical Inc. secured a $23M Series D led by Vertex Ventures HC and Treo Ventures, with participation from Action Potential Venture Capital, Windham Venture Partners & Olympus Innovation Ventures. SOTIO Biotech & Biocytogen announced a research collaboration, exclusive option and license agreement. Under the agreement, Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million. Full-Life Technologies agree a $571.5M deal with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound.   Asceneuron SA secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Disease.

15

1 Comment

🚀 Biopharma Market Expansion: Key Takeaways As biopharma companies explore new markets, it's crucial for leaders to tailor their approach to the unique nuances of each market. Here are some critical insights: 1️⃣ Revenue Potential: By 2028, markets outside the US are projected to generate US$120 billion in revenue, presenting substantial growth opportunities. 2️⃣ 2023 Revenues: Non-US markets accounted for 56% of global biopharma revenue in 2023, up from 52% in 2020. This trend underscores the growing importance of international markets. 3️⃣ Patent Cliff: The industry faces a $200 billion revenue risk from expiring patents by 2030, pushing companies to diversify globally. 4️⃣ Global Market Size: The global biopharma market was valued at US$1.4 trillion in 2023, highlighting the vast scale and potential of the industry. 5️⃣ Strategy Models: Large biopharmas (≥ US$20 billion annual revenue) prefer direct presence in significant markets, while smaller firms (≤ US$5 billion) often opt for distributor partnerships in complex regions. 6️⃣ Operational Challenges: Tailored entry strategies are essential due to varying regulatory, reimbursement, and tax considerations across different countries. 7️⃣ Strategic Focus: Companies should prioritize specific countries, develop tailored entry models, establish robust launch sequences, and build cross-functional capabilities to mitigate risks. Planning and executing a well-thought-out international expansion strategy can help biopharma companies maximize revenue potential and patient reach worldwide. 🌍💉 #Biopharma #MarketExpansion #GlobalGrowth #Biotech #Pharmaceuticals #Strategy #RevenueGrowth P.S. How is your company planning to navigate these market opportunities in 2024? Share your insights below.

3

Kailera Therapeutics' recent $400M launch, backed by drugs developed in China, underscores a growing trend in the biotech world: cross-border collaboration to accelerate access to innovative therapies. The significance of raising $400M at Series A, with backing from prominent investors like Atlas Venture, Bain Capital Life Sciences, and RTW Investments, LP, is substantial. It signals strong confidence in Kailera’s pipeline and strategy. This early funding positions the company as a serious contender in the obesity treatment market, enabling rapid clinical progress and the potential to outpace smaller competitors. Ron Renaud Bruce Booth Adam Koppel Roderick Wong Metsera #Biotech #LifeSciences #HealthcareInnovation #MedicalResearch #Pharma #DrugDevelopment #VentureCapital #BiotechInvesting #ClinicalTrials #Innovation #BiotechStartup #PrecisionMedicine

8

💥 Top 5 MSL Frustrations and How to Overcome Them💥 Check out this weeks MSL Talk podcast with guests Patrina Pellett, PhD, Medical Excellence Lead at MSL Mastery and Sarah Snyder, Medical Affairs Recruiter at The Carolan Group who discuss common frustrations faced by Medical Science Liaisons, exploring the top challenges and offering practical solutions. In this episode, we discuss… 👉 The top 5 most common MSL frustrations 👉 Practical ways to overcome field and personal challenges 👉 The importance of addressing self doubt and imposter syndrome This episode is sponsored by MSL Mastery, helping Medical Science Liaisons and aspiring MSLs to excel in their careers and lives through courses, coaching, and community. For more details, please visit MSLmastery (dot) com. The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #realworldevidence #careers

30

10 Comments

Day One Biopharmaceuticals has entered into a $1.2 billion agreement with MabCare Therapeutics, a Chinese biotech from Shanghai, for the exclusive rights to DAY301, an innovative antibody-drug conjugate (ADC) targeting solid tumors. Key highlights: • Upfront Payment: $55 million • Potential Milestones: $1.15 billion • Royalties: Single-digit Having achieved FDA investigational approval, Day One is advancing towards phase 1 clinical trials. DAY301, originally known as MTX-13, targets PTK7, a highly conserved protein overexpressed in numerous adult and pediatric cancers, including esophageal, ovarian, lung, endometrial, neuroblastoma, rhabdomyosarcoma, and osteosarcoma. Unlike other ADCs, DAY301 focuses on PTK7, offering a unique approach. With the ADC field heating up, it will be interesting to see what impact DAY301 will have in this competitive landscape… This deal, which excludes Greater China for development and commercialization rights, comes amid the proposed BIOSECURE Act’s efforts to limit U.S.-China biotech collaborations by reducing dependency on Chinese firms due to national security concerns, raising the question: with this looming threat, will similar partnerships soon become impossible?

38

1 Comment

GC Therapeutics is about to redefine cell therapy! With its TFome™ platform, it could accelerate iPSC-based therapy production by up to 100 times. Backed by $75 million from prominent investors like Flagship Pioneering, a16z Bio + Health, and Mubadala Capital, this innovation has the potential to lower costs and fast-track personalized medicine to the broader market. Co-founded by George Church, this launch signals a future where cutting-edge therapies become more accessible and scalable, fostering competition and rapid advancements. The next phase of cell therapy is approaching—and it’s moving faster than anticipated. #Biotech #CellTherapy #PersonalizedMedicine #Innovation #StemCells #GeneTherapy #FutureOfMedicine Parastoo Khoshakhlagh, Ph.D. Cormorant Asset Management, LP Raymond J. Kelleher, MD, PhD Alaa Halawa Andreessen Horowitz Vineeta Agarwala, MD PhD Harvard Medical School Wyss Institute at Harvard University Michelle Werner

15